Literature DB >> 33551200

Variations in incidence and mortality rates of endometrial cancer at the global, regional, and national levels, 1990-2019.

Baoxia Gu1, Xiaogai Shang2, Mengqing Yan3, Xiao Li3, Wei Wang3, Qi Wang4, Cuilian Zhang5.   

Abstract

BACKGROUND: Endometrial cancer (EC) is a commonly diagnosed cancer in women. A comprehensive knowledge of its epidemiological features is essential for understanding the disease burden and guiding prevention strategies.
METHODS: We retrieved the incidence and mortality data of EC from the Global Burden of Disease database. Estimated average percentage change (EAPC) was used to quantify the trends of the age-standardized incidence and mortality rates (ASIR and ASMR, respectively) of EC from 1990 to 2019.
RESULTS: Globally, the ASIR of EC significantly increased by 0.69% (95% confidence interval [CI] 0.57-0.81%) per year between 1990 and 2019. This increasing trend was also observed in 160 countries or territories, regardless of the sociodemographic status. The most pronounced increase was found in Italy (EAPC = 4.81, 95% CI, 4.10-5.53), followed by Saudi Arabia and Singapore. Between 1990 and 2019, the ASMR of EC decreased significantly worldwide (EAPC = -0.85, 95% CI, -0.93 to -0.76) but increased significantly in 91 countries or territories, with the highest increase in Lesotho (EAPC = 3.27, 95% CI, 2.81-3.74). The ASMR-ASIR ratio of EC was higher in developing countries than in developed countries. This ratio showed a decreasing trend at the national level over the past three decades.
CONCLUSIONS: EC incidence has ubiquitously increased worldwide. EC mortality has decreased at the global level but increased in many countries. More efforts are required to alleviate the disease burden of EC.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Disease burden; Endometrial cancer; Incidence; Mortality

Year:  2021        PMID: 33551200     DOI: 10.1016/j.ygyno.2021.01.036

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  7 in total

Review 1.  Quantifying the Effect of Physical Activity on Endometrial Cancer Risk.

Authors:  Sarah J Kitson; Olivia Aurangzeb; Jawaria Parvaiz; Artitaya Lophatananon; Kenneth R Muir; Emma J Crosbie
Journal:  Cancer Prev Res (Phila)       Date:  2022-09-01

2.  Metabolic Syndrome as a Risk Factor of Endometrial Cancer: A Nationwide Population-Based Cohort Study of 2.8 Million Women in South Korea.

Authors:  HyunA Jo; Se Ik Kim; Wenyu Wang; Aeran Seol; Youngjin Han; Junhwan Kim; In Sil Park; Juwon Lee; Juhwan Yoo; Kyung-Do Han; Yong Sang Song
Journal:  Front Oncol       Date:  2022-06-16       Impact factor: 5.738

3.  Paired box 8 facilitates the c-MYC related cell cycle progress in TP53-mutation uterine corpus endometrial carcinoma through interaction with DDX5.

Authors:  Ping Qiu; Youkun Jie; Cheng Ma; Huifeng Chen; Yunna Qin; Kaijia Tu; Liqun Wang; Ziyu Zhang
Journal:  Cell Death Discov       Date:  2022-06-07

Review 4.  Glycosylation and its research progress in endometrial cancer.

Authors:  Congli Pu; Kai Xu; Yingchao Zhao
Journal:  Clin Transl Oncol       Date:  2022-06-25       Impact factor: 3.340

5.  The Metabolomic Approach for the Screening of Endometrial Cancer: Validation from a Large Cohort of Women Scheduled for Gynecological Surgery.

Authors:  Jacopo Troisi; Antonio Mollo; Martina Lombardi; Giovanni Scala; Sean M Richards; Steven J K Symes; Antonio Travaglino; Daniele Neola; Umberto de Laurentiis; Luigi Insabato; Attilio Di Spiezio Sardo; Antonio Raffone; Maurizio Guida
Journal:  Biomolecules       Date:  2022-09-02

6.  Calcium-Related Genes Predicting Outcomes and Serving as Therapeutic Targets in Endometrial Cancer.

Authors:  Ting Huang; Xuan Feng; Jiaqi Wang; Jingyi Zhou; Jianliu Wang
Journal:  Cells       Date:  2022-10-08       Impact factor: 7.666

7.  Livin/BIRC7 gene expression as a possible diagnostic biomarker for endometrial hyperplasia and carcinoma.

Authors:  Basma K Elmekkawy; Rasha M S Shoaib; Amal K Seleem; Dalia Shaalan; Entsar A Saad
Journal:  J Genet Eng Biotechnol       Date:  2021-09-26
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.